LAUSR

Results: 14 patients received oxaliplatin containing chemotherapy reintroduction. Median age was 70 years old(range:46-76 years old).10 patients were male, PS over 1 were 4 patients.10 patients were left side colon cancer, 4 patients were right side colon cancer. 6 patients were RAS mutant. All patients were refractory to fluoropyrimidines, bevacizumab and inotecan. In RAS wild patients, 7 patients(88%) were refractory to anti EGFR rntibodies.TAS-102 and regorafenib was administrated only one patient. 5 patients were refractory to first administration of oxaliplatin, 9 patients discontinued by other reason. Median oxaliplatin free time was 11.9 months(range:3.0-36.9 months).Median progression free survival was 5.2months(95% CI: 1.2-7months), and median overall survival was 13.8months (95% CI: 6.6-16.2 months).In patients who had measurable lesion, response rate was 7% and disease control rate was 50%.